EGFR Protein Expression of KRAS Wild-Type Colorectal Cancer: Predictive Value of the Sidedness for Efficacy of Anti-EGFR Therapy

[1]  K. Almhanna,et al.  Impact of Primary Tumor Location on First-line Bevacizumab or Cetuximab in Metastatic Colorectal Cancer. , 2018, Reviews on recent clinical trials.

[2]  Y. Baskın,et al.  Difference Between Left-Sided and Right-Sided Colorectal Cancer: A Focused Review of Literature , 2018, Gastroenterology research.

[3]  Jeffrey S. Morris,et al.  Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes , 2017, Clinical Cancer Research.

[4]  P. Philip,et al.  Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers , 2017, Oncotarget.

[5]  D. Cao,et al.  The impact of primary tumor location on efficacy of cetuximab in metastatic colorectal cancer patients with different Kras status: a systematic review and meta-analysis. , 2017, Oncotarget.

[6]  D. Cao,et al.  The impact of primary tumor location on efficacy of cetuximab in metastatic colorectal cancer patients with different Kras status: a systematic review and meta-analysis , 2017, Oncotarget.

[7]  E. Van Cutsem,et al.  Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials , 2017, JAMA oncology.

[8]  S. Barni,et al.  Prognostic Survival Associated With Left-Sided vs Right-Sided Colon Cancer: A Systematic Review and Meta-analysis , 2017, JAMA oncology.

[9]  Man Li,et al.  Primary tumor site and anti-EGFR monoclonal antibody benefit in metastatic colorectal cancer: a meta-analysis. , 2017, Future oncology.

[10]  J. Guinney,et al.  Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer , 2017, Nature Reviews Cancer.

[11]  U. Güller,et al.  Better survival in right-sided versus left-sided stage I - III colon cancer patients , 2016, BMC Cancer.

[12]  D. Tu,et al.  Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17. , 2015, European journal of cancer.

[13]  B. Ghanim,et al.  Subtype-specific KRAS mutations in advanced lung adenocarcinoma: a retrospective study of patients treated with platinum-based chemotherapy. , 2014, European journal of cancer.

[14]  F. Hirsch,et al.  Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies. , 2013, European journal of cancer.

[15]  Zuyao Yang,et al.  EGFR gene copy number as a predictive biomarker for the treatment of metastatic colorectal cancer with anti-EGFR monoclonal antibodies: a meta-analysis , 2012, Journal of Hematology & Oncology.

[16]  J. Berlin,et al.  Lack of Correlation between Epidermal Growth Factor Receptor Status and Response to Panitumumab Monotherapy in Metastatic Colorectal Cancer , 2010, Clinical Cancer Research.

[17]  L. Schwartz,et al.  Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Chan Zeng,et al.  Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.